Description
Capeda belongs to the group of medicines called “cytostatic agents”, which stop the growth of cancer cells. Capeda Tablets contain 150mg or 500mg capecitabine, which itself is not a cytostatic agent. Only after being absorbed by the body is it changed into an active anti-cancer agent (more in tumour tissue than in normal tissue).
Indications
Capeda is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer (see section 5.1 of SPC).
Capeda is indicated for the treatment of metastatic colorectal cancer (see section 5.1 of SPC).
Capeda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen (see section 5.1 of SPC).
Capeda in combination with docetaxel (see section 5.1) is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
Subject to medical prescription
Pharmaceutical form: 150 mg film-coated tablets x 60 tablets
NHIF code:
ICD:C50; C16; C18; C19; C20
Pharmaceutical form: 500 mg film-coated tablets x 120 tablets
NHIF code:
ICD:C50; C16; C18; C19; C20
АТС code: L01BC06
